InsiderTrades

Form 4 for EOG EOG Resources

Accepted 2022-03-07 00:00:00 ET · period of report 2022-03-03 · accession 0001127602-22-008339 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2022-03-07 2022-03-03 EOG Donaldson Michael P EVP, Gen. Counsel, Corp Sec F - Tax $117.21 -4,298 116.1K -4% -$503.8K
DM 2022-03-07 2022-03-03 EOG Donaldson Michael P EVP, Gen. Counsel, Corp Sec M - OptEx $87.36 +48.4K 120.3K +67% +$4.23M
DM 2022-03-07 2022-03-03 EOG Donaldson Michael P EVP, Gen. Counsel, Corp Sec D - Sale to Iss $117.22 -36.1K 115.1K -24% -$4.23M
DM 2022-03-07 2022-03-03 EOG Donaldson Michael P EVP, Gen. Counsel, Corp Sec S - Sale+OE $117.15 -11.3K 114.0K -9% -$1.33M
DM 2022-03-07 2022-03-03 EOG Donaldson Michael P EVP, Gen. Counsel, Corp Sec M - OptEx $0.00 -48.4K 4,160 -92% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-03-03 F D 1,143 $117.24 113,999.43 D — —
2 Common Common Stock 2022-03-03 M A 17,194 $95.05 125,254.43 D — —
3 Common Common Stock 2022-03-03 D D 13,943 $117.22 111,311.43 D — —
4 Common Common Stock 2022-03-03 F D 1,279 $117.22 110,032.43 D — —
5 Common Common Stock 2022-03-03 M A 19,080 $96.29 129,112.43 D — —
6 Common Common Stock 2022-03-03 D D 15,672 $117.23 113,440.43 D — —
7 Common Common Stock 2022-03-03 F D 1,201 $117.23 112,239.43 D — —
8 Common Common Stock 2022-03-03 S D 9,231 $117.14 104,768.43 D — — (F1) The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $117.12 to $117.168, inclusive. The reporting person undertakes to provide to EOG Resources, Inc., any security holder of EOG Resources, Inc. or the staff of the United States Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
9 Common Common Stock 2022-03-03 S D 2,096 $117.19 113,999.43 D — —
10 Common Common Stock 2022-03-03 F D 675 $117.12 116,095.43 D — —
11 Common Common Stock 2022-03-03 D D 1,303 $117.12 116,770.43 D — —
12 Common Common Stock 2022-03-03 M A 4,074 $37.44 118,073.43 D — —
13 Common Common Stock 2022-03-03 D D 5,172 $117.24 115,142.43 D — —
14 Common Common Stock 2022-03-03 M A 8,075 $75.09 120,314.43 D — —
15 Derivative Stock Appreciation Rights 2022-03-03 M D 19,080 $0.00 0 D $96.29 · 2018-09-25 to 2024-09-25 19,080 Common Stock (F3) The SARs granted became exercisable in increments of 33%, 33% and 34% on each of the first three anniversaries, respectively, of the September 25, 2017 date of grant. The SARs granted became fully exercisable on September 25, 2020. This exercise did not involve any open-market sale of the Issuer's Common Stock.
16 Derivative Stock Appreciation Rights 2022-03-03 M D 4,074 $0.00 8,161 D $37.44 · 2021-09-28 to 2027-09-28 4,074 Common Stock (F5) The SARs granted become exercisable in increments of 33.3%, 33.3% and 33.4% on each of the first three anniversaries, respectively, of the September 28, 2020 date of grant. The SARs granted will become fully exercisable on September 28, 2023.
17 Derivative Stock Appreciation Rights 2022-03-03 M D 17,194 $0.00 0 D $95.05 · 2017-09-29 to 2023-09-29 17,194 Common Stock (F2) The SARs granted became exercisable in 25 percent increments beginning one year from the September 29, 2016 date of grant and on each of the next three grant date anniversaries. The SARs granted became fully exercisable on September 29, 2020. This exercise did not involve any open-market sale of the Issuer's Common Stock.
18 Derivative Stock Appreciation Rights 2022-03-03 M D 8,075 $0.00 4,160 D $75.09 · 2020-09-26 to 2026-09-26 8,075 Common Stock (F4) The SARs granted become exercisable in increments of 33%, 33% and 34% on each of the first three anniversaries, respectively, of the September 26, 2019 date of grant. The SARs granted will become fully exercisable on September 26, 2022. This exercise did not involve any open-market sale of the Issuer's Common Stock.